Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study was to investigate whether there is a link between clinical and biological variables and bioassay high xaban in elderly patients as part of an unscheduled hospitalization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study

NCT02464488

Atrial Fibrillation

COMPLETED

Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

NCT04539301

Anticoagulation Venous Thromboembolism Atrial Fibrillation

RECRUITING

Glomerular Filtration Rate-Estimating Equations During Use of Direct Oral Anticoagulants in Elderly Patients

NCT02964546

Atrial Fibrillation Elderly Patients Chronic Kidney Disease

TERMINATED

Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

NCT02171468

Healthy

COMPLETED PHASE1

Pilot Study: Comparison of Patients' Knowledge of Direct Oral Anticoagulants in Post-hospitalization Between 2 Cardiology Departments Offering or Not a Pharmaceutical Interview During Hospitalization

NCT04674202

Atrial Fibrillation Deep Vein Thrombosis Pulmonary Embolism

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood test

bioassay xaban

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 75 years
* Entering SAU or MPG (Nantes University Hospital) as part of an unscheduled hospitalization for acute or subacute disease (About MPG, will be included patients admitted to the department within 48 hours of calling the doctor)
* In xaban to entry (dabigatran, rivaroxaban, Apixaban) for non-valvular atrial fibrillation
* In whom hemostasis tests will be prescribed as part of usual care
* Patient has given its verbal agreement

Exclusion Criteria

Patients with the following criteria may not be included:

* Patients refusing to participate in the study
* Patients under guardianship
* Inability to obtain the date and time of the last dose of xaban

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No